---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-086244"
form_type: "8-K"
ticker: "APUS"
cik: "0001894525"
company_name: "Apimeds Pharmaceuticals US, Inc."
filed_at: "2026-08-06T21:25:33+00:00"
generated_at: "2026-08-06T21:26:05.907346+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Apimeds appoints Dr. Christopher Kim as Chief Scientific Officer

## Summary
- Dr. Christopher Kim appointed Chief Scientific Officer effective August 5, 2026.
- He will lead scientific, clinical, and regulatory development of the APITOX program.
- Dr. Kim has extensive expertise in APITOX research, development, and clinical advancement.
- Appointment provides continuity and strengthens long-term development strategy toward commercialization.

## SEC filing metadata
- accession: 0001213900-26-086244
- form_type: 8-K
- ticker: APUS
- cik: 0001894525
- company_name: Apimeds Pharmaceuticals US, Inc.
- filed_at: 2026-08-06T21:25:33+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1894525/000121390026086244/0001213900-26-086244-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1894525/000121390026086244/ea0301025-8k_apimeds.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-086244
- JSON: https://secwatch.observer/filing/0001213900-26-086244.json
- Plain text: https://secwatch.observer/filing/0001213900-26-086244.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.